research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Due to the mutiny of the Military Police of Espírito Santo State in which the agents demanded the correction of the remuneration for inflation, along with retroactive payments, criminal gangs and drug traffickers took advantage of the situation and a crime wave of violence, carjacking and looting spread across Espírito Santo, with most public services and businesses being closed. The Espírito Santo state government called in assistance from the National Public Security Force and the Brazilian Armed Forces to restore law and order in Vitória and other cities until military policemen began to return to their duties after two weeks of strike action. By 25 February, all military policemen in Espírito Santo had ended their strikes. At least 215 people were killed in the violence.
In 2002, they developed an unnatural base pair between 2-amino-8-(2-thienyl)purine (s) and pyridine-2-one (y) that functions in vitro in transcription and translation, for the site-specific incorporation of non-standard amino acids into proteins. In 2006, they created 7-(2-thienyl)imidazo[4,5-b]pyridine (Ds) and pyrrole-2-carbaldehyde (Pa) as a third base pair for replication and transcription. Afterward, Ds and 4-[3-(6-aminohexanamido)-1-propynyl]-2-nitropyrrole (Px) was discovered as a high fidelity pair in PCR amplification. In 2013, they applied the Ds-Px pair to DNA aptamer generation by in vitro selection (SELEX) and demonstrated the genetic alphabet expansion significantly augment DNA aptamer affinities to target proteins.
The earliest-known synapsid satisfying Kemp's definitions is Tikitherium, dated 225 Ma, so the appearance of mammals in this broader sense can be given this Late Triassic date. However, this animal may have actually evolved during the Neogene.
== Role in bone remodeling == Osteoid plays a central role in the continuous process of bone remodeling. During the bone formation phase of remodeling, osteoblasts deposit new osteoid at sites previously resorbed by osteoclasts. The bone remodeling cycle involves distinct phases:
== History == The history of today's Gelita AG in Eberbach dates back to 1875, when the production of gelatin was started in Schweinfurt. Gelita was preceded by the founding of the "Gebrüder Köpff Company", Heinrich Koepff's small tannery, in 1883. Shaken by the economic crisis of the time, Heinrich saw a way out of his misery in gelatin production. The raw material for this could be purchased cheaply, as it was produced in the large tanneries as residual material. With around 60 employees, the factory was already producing photographic gelatin in 1884, which was an important material for the rapidly emerging photography in the 19th century. In 1887, the Koepff brothers acquired the competing company A. & C. Wolff in Heilbronn. Both locations had 320 employees who produced 400 tonnes of gelatin per year. In 1901, a major fire destroyed large parts of the factory. The brothers quarreled over reconstruction. Heinrich went to Heilbronn and Paul Koepff continued to run the rebuilt plant alone under the name Göppinger Gelatin Factory Paul Koepff. In 1911, he sold the factory to DGF AG, which already operated gelatin factories in Schweinfurt and Höchst. Paul Koepff was henceforth on the board of directors and continued to manage his former company as director. In 1929, Paul Koepff jr. took over the management of the Göppingen plant from his father, who died in 1953. The Gelita Brand was introduced in 1934. In 1937, the DGF was accused of violating foreign trade regulations and leading employees were arrested.
Sources: en.wikipedia.org
=== Oral collagen supplements === Preliminary results are promising for the short and long-term use of oral collagen supplements for wound healing and skin aging. Oral collagen supplements also increase skin elasticity, hydration, and dermal collagen density. Collagen supplementation is generally safe with no reported adverse events. Further studies are needed to elucidate medical use in skin barrier diseases such as atopic dermatitis and to determine optimal dosing regimens.
These are available salted or in brine and they are primarily used by medium to large sausage makers who do not want to pay the additional cost for the tubed casing and do not have automatic sausage stuffing and linking machines (which require tubed casings to operate efficiently). These are available in all diameters and in lengths greater than 2 meters. Beef casings are primarily available only salted or in brine. They are measured in sets, not hanks, and the length is 32 meters; this is for beef "rounds" and "middles" only, as beef bung caps are only about 1 meter in length.
=== Detecting mechanical damage to connective tissue === Collagen offers mechanical strength in load bearing tissues in the body such as tendons, ligaments, and bone. As forces are applied to these tissues, the collagen triple helix can be damaged and unwind, and CHPs allow for molecular level detection of mechanical damage in such connective tissues.
=== Oxidative stress === Oxidative stress results from the lack of balance between the systemic production of reactive oxygen species (ROS) and the biological system's capacity to detoxify them or repair the resulting damage. It is known that reactive oxygen species take part in dermal changes taking place outside the cells in both aging caused by internal factors and those caused by external factors. ROS can be created within many dissimilar sources, which include the mitochondria, endoplasmic reticulum and peroxisomes. In normal conditions the binding of ligands to receptor tyrosine kinases (RTKs) activates them, while the various actions of RTKs on the cells' surface are repressed by receptor protein tyrosine phosphatases.
Connective tissue neoplasms including sarcomas such as hemangiopericytoma and malignant peripheral nerve sheath tumor in nervous tissue. Congenital diseases include Marfan syndrome and Ehlers–Danlos syndrome. Myxomatous degeneration – a pathological weakening of connective tissue. Mixed connective tissue disease – a disease of the autoimmune system, also undifferentiated connective tissue disease. Systemic lupus erythematosus (SLE) – a major autoimmune disease of connective tissue Scurvy, caused by a deficiency of vitamin C which is necessary for the synthesis of collagen. Fibromuscular dysplasia is a disease of the blood vessels that leads to an abnormal growth in the arterial wall.
Sources: en.wikipedia.org
Americium has been produced in small quantities in nuclear reactors for decades, and kilograms of its 241Am and 243Am isotopes have been accumulated by now. Nevertheless, since it was first offered for sale in 1962, its price, about US$1,500 per gram (US$43,000/oz) of 241Am, remains almost unchanged owing to the very complex separation procedure. The heavier isotope 243Am is produced in much smaller amounts; it is thus more difficult to separate, resulting in a higher cost of the order US$100,000–US$160,000 per gram (US$2,800,000–US$4,500,000/oz). Americium is not synthesized directly from uranium – the most common reactor material – but from the plutonium isotope 239Pu. The latter needs to be produced first, according to the following nuclear process:
==== South Africa ==== A notice issued by the Medicines Control Council of South Africa on July 5, 2011, stated that it had resolved on July 3, 2011, to withdraw all rosiglitazone-containing medicines from the South African market due to safety risks. It disallowed all new prescriptions of Avandia.
The Houthis, officially known as Ansar Allah or Ansarullah, are a Zaydi revivalist and Shia Islamist political and paramilitary organization that emerged from Yemen in the 1990s. It is predominantly made up of Zaydis, whose namesake leadership is drawn largely from the al-Houthi family. The Houthis are backed by Iran, and they are widely considered part of the Iranian-led Axis of Resistance. The group has been a central player in Yemen's civil war, drawing widespread international condemnation for its human rights abuses, including targeting civilians and using child soldiers. The movement is designated as a terrorist organization by some countries. Under the leadership of Zaydi religious leader Hussein al-Houthi, the Houthis emerged as an opposition movement to Yemeni president Ali Abdullah Saleh, whom they accused of corruption and being backed by Saudi Arabia and the United States. In 2003, influenced by the Lebanese Shia political and military organization Hezbollah, the Houthis adopted their official slogan against the United States, Israel, and the Jewish people. Al-Houthi resisted Saleh's order for his arrest, and he was killed by the Yemeni military in Saada in 2004. His death sparked the Houthi insurgency. Since then, the movement has been mostly led by his brother Abdul-Malik al-Houthi. The organization played a role in the Yemeni Revolution of 2011 by participating in street protests and coordinating with other Yemeni opposition groups. They joined Yemen's National Dialogue Conference but later rejected the 2011 reconciliation deal.
=== Microtemplate polymerization === The addition of a monomer precursor solution and crosslinking agent to a microtemplate, or mold-type device, can initiate polymerization and the formation of nanogels. This method can be used to create nanogels in specific shapes and load them with various small molecules. Lithographic microtemplate polymerization is a similar process that uses a photoinitiator and light to trigger the formation of nanogels. Lithographic microtemplate polymerization can produce smaller nanogels on a length scale of <200 nm, which has a higher resolution compared to microtemplate polymerization that does not require a photoinitiator.
Localized loss including holes, wear, and tear require stabilization. Implementing localized supports such as patches or fills. Stitching can also strengthen damaged areas. Shear fabric overlays are also useful in combination with lower layers of supporting fabrics. Choice of stitching versus overlay should be considered in relation to the overall condition and material of the fabric.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.